Urology News and Research

Latest Urology News and Research

Regnite to treat primary restless legs syndrome launched in Japan

Astellas Pharma Inc. and XenoPort, Inc. announced today that Regnite (gabapentin enacarbil) Extended-Release Tablets will be launched in Japan on July 10, 2012. Regnite is approved in Japan for the treatment of moderate-to-severe primary restless legs syndrome (RLS).

9 Jul 2012

Conference highlights utility of zebrafish for human disorder studies

Zebrafish, popular as aquarium fish, now have an important place in research labs as a model organism for studying human diseases.

8 Jul 2012

Presence of SPDEF protein may predict prostate cancers that are unable to metastasize

Prostate cancer doesn't kill in the prostate - it's the disease's metastasis to other tissues that can be fatal. A University of Colorado Cancer Center study published this week in the Journal of Biological Chemistry shows that prostate cancer cells containing the protein SPDEF continue to grow at the same pace as their SPDEF- cousins, but that these SPDEF+ cells are unable to survive at possible sites of metastasis.

8 Jul 2012

Robot assists in complex uro surgery for pediatric patient

Pediatric specialists of Apollo Hospitals successfully completed a complex surgery on the bladder base of a 7 year old child from Africa with the assistance of a Robot. The child's urethra, the tube from the urinary bladder, was crushed in a road accident.

7 Jul 2012

New optical microscope identifies rare breast cancer cells

The ability to distinguish and isolate rare cells from among a large population of assorted cells has become increasingly important for the early detection of disease and for monitoring disease treatments.

7 Jul 2012

First robot-assisted distal pancreatectomy performed at TJUH

Eugene Allen, a retired police officer and teacher from Sicklerville, N.J., had a decision to make in February, after an MRI revealed a precancerous cyst in his pancreas. It had to be removed, but the question was how?

6 Jul 2012

Prostate cancer patients with CVD are 52% more likely to regret their treatment choices

Prostate cancer patients with cardiovascular disease were 52 per cent more likely to regret their treatment choices than men without problems with their heart or veins, according to a study published in the July issue of the urology journal BJUI International.

3 Jul 2012

Researchers show how aggressive form of multiple myeloma resists chemotherapy

Researchers at Washington University School of Medicine in St. Louis have shown how an aggressive form of multiple myeloma resists chemotherapy.

3 Jul 2012

Gene vital to flu severity discovered

Researchers have discovered that a protein known as PA-X, produced from a ribosomal frameshift mutation in a gene in the influenza A genome, has a substantial impact on host response to the virus.

2 Jul 2012

Sling device a good shot for vaginal prolapse repair

A midurethral sling device added during surgery for vaginal prolapse repair reduces the risk for postoperative urinary incontinence, research shows.

2 Jul 2012

Three-step clinical pathway for CAP reduces length of hospital stay

A three-step pathway helps to reduce the duration of intravenous antibiotic treatment in hospitalized patients with community-acquired pneumonia, show study findings published in the Archives of Internal Medicine.

2 Jul 2012

Prostate Cancer Center of New Jersey earns ACR-ASTRO accreditation in radiation oncology

The Prostate Cancer Center of New Jersey, a partnership between AKSM/Oncology and the Urology Group of New Jersey (UGNJ), is the latest in a rapidly growing list of prostate-only treatment centers to earn the high honor of a three-year term of accreditation in radiation oncology.

2 Jul 2012

Astellas Pharma receives FDA approval for Myrbetriq to treat overactive bladder

The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.

29 Jun 2012

Experts in fluid mechanics to study Chiari malformation

Expertise in fluid mechanics at The University of Akron has attracted funding for a new research center designed to help physicians better diagnose and treat an unusual cause of pain in the head, neck and shoulders. Chiari malformation is a disorder of the neurologic system caused in part by an imbalance in brain and spinal fluid.

28 Jun 2012

Common cold remedy ‘not recommended’ for children

Research suggests that using steam inhalation as a remedy for a blocked nose or sinuses in children can be dangerous due to a high scalding risk associated with this therapy.

27 Jun 2012

Combination of radiation therapies effectively treat prostate cancer, lower chances of recurrence

A recent Phase I/II clinical trial has shown that a new combination of radiation therapies developed at Virginia Commonwealth University Massey Cancer Center escalates radiation doses to safely and effectively treat prostate cancer and lower the risk of recurrence with minimal radiation exposure to nearby healthy tissue and organs.

27 Jun 2012

New type of micromachine can penetrate tissue and overcome cellular barriers

Microscopically small submarines that can swim through our blood to clear out clogged arteries or destroy malignant tumors. This concept may sound utopian, but it isn’t. Various micro- and nanomachines have in fact already been developed.

27 Jun 2012

Astellas submits enzalutamide MAA with EMA for treatment of CRPC

Today, Astellas Pharma Inc. announces the submission of a European marketing authorisation application to the European Medicines Agency (EMA) for enzalutamide for the treatment of men with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.

27 Jun 2012

Exposure to BBzP during pregnancy can increase risk of eczema in children

Prenatal exposure to a ubiquitous household chemical called butylbenzyl phthalate (BBzP) can increase a child's risk for developing eczema, according to research conducted at the Columbia Center for Children's Environmental Health at the Mailman School of Public Health.

26 Jun 2012

Pfizer, Wyeth and PF Prism file suit against Watson over generic Pristiq

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Desvenlafaxine Succinate Extended-release Tablets, 50 mg and 100 mg.

26 Jun 2012